ZEGFROVY (sunvozertinib)
TherapyDizal Pharmaceutical
ZEGFROVY (sunvozertinib) from Dizal Pharmaceutical is a targeted therapy for tumors with EGFR exon 20 insertions.
Approvals
1
Indications
1
Biomarkers
1
Mapped tests
1
Where this therapy is approved with a companion diagnostic
Each row represents a defined combination of indication, biomarker criteria, and ZEGFROVY. Select a testing pathway to see the eligible companion diagnostic tests.
Indication-specific approvals
Approvals where ZEGFROVY is tied to a specific indication and biomarker definition.
| Indication | Biomarker criteria | Notes | |
|---|---|---|---|
Non-Small Cell Lung Cancer (NSCLC) Solid Tumor · Lung | EGFR (HER1)
| View testing pathway → |
Tumor-agnostic approvals
Approvals defined at the solid tumor level where biomarker criteria determine eligibility for ZEGFROVY.
No tumor-agnostic companion diagnostic approvals are currently mapped for this therapy.
Tests used in these approvals
These assays are identified in FDA labeling or sponsor materials as companion diagnostics or acceptable tests when considering ZEGFROVY for eligible patients.
Test
Oncomine Dx Express Test
Life Technologies Corporation (ThermoFisher Scientific)
Method
NGS
Specimen
Tissue (FFPE)
1 approvalView test profile →